- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Company Reports Strong Current Backlog of $22 Million
Tegal Corporation (NASDAQ: TGAL), a leading designer and manufacturer of plasma etch and deposition systems used in the production of integrated circuits and nanotechnology devices, today announced financial results for the Fourth Quarter and Fiscal Year 2007, which ended March 31, 2007. Senior management will conduct an investor conference call to discuss these results and the company's financial outlook in more detail today at 2:00 p.m. Pacific Time, Wednesday, June 27, 2007. More information about the conference call is provided below.
During the first quarter of fiscal 2008, the company reported new bookings of $20 million in systems revenue. The backlog as of June 27, 2007 stands at $22 million, approximately equal to revenues recorded for the entire fiscal year 2007.
The company's cash balance at the end of the fiscal year was $25.8 million, compared to $13.8 million at the end of the prior fiscal year.
As expected, operating losses for the fourth quarter decreased to ($2.0) million from ($2.4) million in the same quarter last year. Litigation and restructuring expenses amounted to $0.6 million during the quarter, while non-cash expenses were approximately $0.6 million. Excluding these charges, operating loss for the fourth quarter was ($0.8) million. The company posted operating losses for the fiscal year of ($13.4) million, which included approximately $2.6 million non-cash charges for depreciation, amortization, and stock compensation expense, $5.4 million of litigation expenses, move and restructuring costs, and $1.9 million in inventory and fixed-asset write-offs. Excluding these charges, operating loss for the fiscal year was ($3.3) million.
The company shipped a total of 17 plasma etch and deposition systems during the year, including several systems to 4 new customers, continuing its penetration of novel applications and new materials for semiconductor and MEMS devices incorporated into cell phones, wireless and other electronic devices.
The company reached a settlement of its lawsuit against Advanced Modular Sputtering (AMS), Agilent Technologies and the Avago Entities, resulting in a cash payment of $19.5 million, the transfer of all assets of AMS to Tegal, and the subsequent liquidation of AMS.
"Fiscal 2007 was a watershed year for the company and I am very pleased with our accomplishments," said Thomas Mika, Chairman, President and CEO of Tegal Corporation. "We were able to solidify a large sales increase from the prior year while significantly improving our cost structure and operational efficiency. We also saw a successful outcome from our litigation which resulted in a large increase to our cash balance and now allows us to focus on growing and improving our business. Our current product portfolio and upcoming new system offerings are positioned well to take advantage of the demand for new materials for semiconductor and MEMS devices incorporated into fast growing markets such as smart phones, wireless applications and other new electronic sensors. The success of our turn-around and product positioning is evident with the many orders that we have taken since the end of the fiscal year and our very strong current backlog of $22 million. Looking forward to this fiscal year, we will still have some variability in results early in the year as not all of our new orders will ship immediately. However, our backlog and new order momentum make us very optimistic about our prospects for later in the year and are very encouraging signs for our overall goal of reaching profitability."
Revenues for the fiscal fourth quarter of 2007 were $6.2 million, an increase of 2% from $6.1 million for the fiscal fourth quarter of 2006. Tegal reported a net loss of ($2.0) million, or ($0.28) per share, for the quarter, compared to a net loss of ($1.8) million, or ($0.26) per share in the comparable quarter one year ago.
For the fiscal year ended 2007, revenues were $22.3 million, an increase of 2% from $21.8 million in the prior fiscal year. Tegal reported a net loss of ($13.2) million, or ($1.87) per share for the fiscal year, compared to a net loss of ($8.9) million, or ($1.50) per share in the prior fiscal year.
Gross profits for the fiscal fourth quarter of 2007 were 31.5% compared to 20.1% in the same quarter one year ago. For the fiscal year ended 2007, gross profits were 24.8% versus 27.7% in the prior fiscal year.
The operating loss for the fourth quarter was ($2.0) million compared to a loss of ($2.4) million in the same quarter one year ago. The Company's operating loss for the full year was ($13.4) million, compared to an operating loss of ($8.8) million in the prior year. Tegal's operating loss for the year included non-cash charges for depreciation, amortization, and stock compensation expense, as well as significant litigation, move and restructuring charges.
Cash at the end of the fiscal fourth quarter of 2007 was $25.8 million, up $12.0 million from the same quarter one year ago.
$19.5 million remains in a Litigation Suspense liability account, pending resolution of the company's dispute with its attorneys over the amount payable under the settlement agreement.
Investor Conference Call
The company will host a conference call for investors today (Wednesday, June 27) at 5:00 p.m. (EDT) / 2:00 p.m. (PDT). The dial-in phone numbers are (866) 271-0675 or (617) 213-8892. Investors should reference passcode 40914495. A digital recording will be made available one hour after the completion of the conference call, and it will be accessible through midnight on Wednesday, July 4th, 2007. To access, investors should dial (888) 286-8010 or (617) 801-6888 and enter passcode: 98408962. The conference call also will be available live via the Investor Section of the Company's website at: www.tegal.com. A replay of the teleconference, along with a copy of the Company's earnings release, will be available on the Company's website, as well.
Safe Harbor Statement
Except for historical information, matters discussed in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements, which are based on assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words "anticipate," "believe," "estimate," "expect," "intend," "project" or similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company including, but not limited to industry conditions, economic conditions, acceptance of new technologies and market acceptance of the Company's products and services. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph. For a further discussion of these risks and uncertainties, please refer to the Company's periodic filings with the Securities and Exchange Commission.
About Tegal Corporation
Tegal provides process and equipment solutions to leading edge suppliers of advanced semiconductor and nanotechnology devices. Incorporating unique, patented etch and deposition technologies, Tegals system solutions are backed by over 35 years of advanced development and over 100 patents. Some examples of devices enabled by Tegal technology are energy efficient memories found in portable computers, cell phones, PDAs and RFID applications; megapixel imaging chips used in digital and cell phone cameras; power amplifiers for portable handsets and wireless networking gear; and MEMS devices like accelerometers for automotive airbags, microfluidic control devices for ink jet printers; and laboratory-on-a-chip medical test kits.
For more information about Tegal Corporation, visit: http://www.tegal.com
TEGAL CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
|March 31,||March 31,|
|Cash and cash equivalents||$||25,776||$||13,787|
|Trade receivables, net||6,634||5,265|
|Prepaid expenses and other current assets||991||1,270|
|Total current assets||38,968||28,022|
|Property and equipment, net||1,351||1,849|
|Intangible assets, net||1,161||1,474|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accrued expenses and other current liabilities||3,590||1,975|
|Total current liabilities||27,239||5,975|
|Long-term portion of capital lease obligation||−||2|
|Other long-term obligations||−||6|
|Additional paid-in capital||122,473||120,592|
|Accumulated other comprehensive income||240||532|
|Total stockholders’ equity||14,417||26,040|
TEGAL CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
|Cost of revenue||4,242||4,836||16,736||15,741|
|Gross profit (loss)||1,955||1,217||5,527||6,016|
|Research and development||1,507||1,327||4,646||4,753|
|Sales and marketing||952||868||3,909||2,963|
|General and administrative||1,497||1,373||10,347||7,139|
|In-process research and development||−||−||−||−|
|Total operating expenses||3,956||3,568||18,902||14,855|
|Operating income (loss)||(2,001)||(2,351)||(13,375)||(8,839)|
|Other income (expense), net|
|Interest expense, net||291||125||643||291|
|Other income (expense)||(295)||(94)||(481)||(864)|
|Total other income (expense), net||(4)||31||162||(573)|
|Net loss before taxes||(2,005)||(2,320)||(13,213)||(9,412)|
|Net loss after taxes||$||(2,005)||$||(1,788)||$||(13,213)||$||(8,880)|
|Net loss per share, basic and diluted||$||(0.28)||$||(0.26)||$||(1.87)||$||(1.50)|
|Shares used in per share computation:|
For more information, please click here
Christine Hergenrother (Vice President & CFO),
The Blue Shirt Group
Rakesh Mehta, 415-217-7722
Chris Danne, 415-217-7722
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Designing ultrasound tools with Lego-like proteins August 29th, 2016
Designing ultrasound tools with Lego-like proteins August 29th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
University of Puerto Rico and NASA back in the news XEI reports August 23rd, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016